Literature DB >> 2050192

Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide.

Q L Gong1, T Hedner, J Hedner, R Björkman, G Nordberg.   

Abstract

Morphine and its major metabolites, morphine-3-glucuronide and morphine-6-glucuronide, were given intracerebroventricularly (i.c.v.) to rats. The antinociceptive effects were assessed in the tail-flick and hot-plate tests as well as the writhing test. Ventilatory effects were studied in halothane-anaesthetized rats. Based on calculated ED50 values, morphine-6-glucuronide was approximately 200 times more potent that morphine itself in the tail-flick and hot-plate tests. In the writhing test the difference in ED50 was approximately 9-fold. Morphine and morphine-6-glucuronide administered i.c.v. induced dose-related decreases in minute ventilation in the dose range 2.7 x 10(-9)-1.3 x 10(-7) mol. The dose-response curve for minute ventilation was steeper for morphine-6-glucuronide than for morphine. Morphine-6-glucuronide was approximately 10 times more potent than morphine in depressing minute ventilation. Morphine-6-glucuronide reduced both tidal volume and respiratory frequency, while morphine reduced only the tidal volume. Morphine-3-glucuronide, in contrast, increased both tidal volume and respiratory frequency, causing an increase in minute ventilation. Apnoea was elicited after the highest doses of morphine-6-glucuronide but not of morphine. The potency difference for depression of minute ventilation between morphine-6-glucuronide and morphine corresponded well to the difference in the writhing test but not to the potency difference in the tail-flick or hot-plate tests. The ventilatory depression induced by morphine and morphine-6-glucuronide was readily reversed by naloxone, while the hyperventilation caused by morphine-3-glucuronide was slightly potentiated by the opioid antagonist. Naloxone pretreatment completely blocked the ventilatory depression induced by morphine-6-glucuronide. These results show that the potent ventilatory depression induced by morphine-6-glucuronide is related to its antinociceptive effects in rats. Furthermore, the fact that morphine-3-glucuronide stimulated ventilation and that morphine had a more shallow ventilatory dose-response curve compared to morphine-6-glucuronide may indicate that morphine-3-glucuronide is a functional antagonist of the depressive effects of morphine and morphine-6-glucuronide on ventilation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050192     DOI: 10.1016/0014-2999(91)90199-z

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  31 in total

1.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

2.  Induction of morphine-6-glucuronide synthesis by heroin self-administration in the rat.

Authors:  Maria Meringolo; Valentina Brusadin; Maria T De Luca; Christian Montanari; Christian L Montanari; Letizia Antonilli; Paolo Nencini; Aldo Badiani
Journal:  Psychopharmacology (Berl)       Date:  2011-10-21       Impact factor: 4.530

3.  [The role of morphine-6-glucuronide during longterm administration of morphine.].

Authors:  M Prokopek; A Ziegler
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

4.  Morphine-6-O-beta-D-glucuronide but not morphine-3-O-beta-D-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes.

Authors:  S V Löser; J Meyer; S Freudenthaler; M Sattler; C Desel; I Meineke; U Gundert-Remy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

5.  HPLC with laser-induced native fluorescence detection for morphine and morphine glucuronides from blood after immunoaffinity extraction.

Authors:  Y Hupka; J Beike; J Roegener; B Brinkmann; G Blaschke; H Köhler
Journal:  Int J Legal Med       Date:  2005-01-19       Impact factor: 2.686

Review 6.  Clinical pharmacokinetics of sedatives in neonates.

Authors:  E Jacqz-Aigrain; P Burtin
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

7.  Effects of morphine metabolites on micturition in normal, unanaesthetized rats.

Authors:  Y Igawa; D Westerling; A Mattiasson; K E Andersson
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

8.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

9.  Randomised, double blind trial of two loading dose regimens of diamorphine in ventilated newborn infants.

Authors:  D P Barker; J Simpson; M Pawula; D A Barrett; P N Shaw; N Rutter
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-07       Impact factor: 5.747

10.  Different distribution of morphine and morphine-6 beta-glucuronide after intracerebroventricular injection in rats.

Authors:  Takashi Okura; Masanori Saito; Misato Nakanishi; Noriyuki Komiyama; Aki Fujii; Shizuo Yamada; Ryohei Kimura
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.